NEW YORK, Jan. 28 (GenomeWeb News) -- Beyond Genomics of Waltham, Mass, and GlaxoSmithKline today announced a research collaboration for drug discovery and development in metabolic diseases, following a pilot project that began in December 2002, the companies said in a statement.
Under the agreement, GSK will pay Beyond Genomics an undisclosed upfront fee and will fund the research program for its full term. Additional financial terms of the agreement were not disclosed. The agreement includes options and license agreements.
Beyond Genomics will apply its technology to elucidate disease pathways and identify biomarkers of disease state and drug response using its systems biology approach, which includes its molecular phenotyping platform to simultaneously measure transcripts, proteins, and metabolites, and integrate the data sets produced with clinical information, according to the company.